Condition

Platinum-resistant Ovarian Cancer clinical trials and research

• 17Clinical trials
• 8NIH research projects
• 7Countries

Newest Platinum-resistant Ovarian Cancer clinical trials

All recruiting trials (17)

• SYS6043 plus standard chemo vs standard chemo in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer

  This study tests SYS6043 against the doctor’s choice chemotherapy in adults with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer to see which treatment works better.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Beijing, Beijing Municipality · NCT07708753

• OPB-201 therapy for recurrent endometrial and platinum-resistant ovarian cancer

  A one-time treatment with a patient’s own T cells engineered to target PRAME is being tested to see if it is safe and what dose works best for adults with recurrent endometrial cancer or platinum-resistant ovarian cancer.

  Recruiting at 5 sites Phase 1 Outpace Bio, Inc. · San Francisco, California and 4 other locations · NCT07664735

• Rina-S extension study in platinum-resistant ovarian cancer in China

  This study tests whether Rina-S works as well as standard chemotherapy options for people with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer in China.

  Recruiting at 17 sites Phase 3 Genmab · Changchun and 16 other locations · NCT07604766

• GB-5267 for platinum-resistant ovarian, peritoneal, or fallopian tube cancer

  This early-phase trial test GB-5267 in adults with platinum-resistant ovarian cancer to see if it is safe and can help shrink tumors.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT07489287

• MUC16-targeted antibody-drug HWK-016 for advanced ovarian and endometrial cancer

  This will test HWK-016, an antibody-drug that targets MUC16, in adults with advanced or metastatic ovarian or endometrial cancer, including platinum-resistant ovarian cancer.

  Recruiting at 9 sites Phase 1 Whitehawk Therapeutics, Inc. · Little Rock, Arkansas and 11 other locations · NCT07470853

• HWK-007, a PTK7-targeted antibody‑drug conjugate for advanced PTK7-positive ovarian, endometrial, and certain non‑squamous lung cancers

  This study will try HWK-007, a PTK7-targeted antibody‑drug conjugate given every three weeks, to see if it can shrink or control advanced PTK7-positive ovarian, endometrial, or non-squamous EGFR wild-type lung cancers.

  Recruiting at 10 sites Phase 1 Whitehawk Therapeutics, Inc. · Little Rock, Arkansas and 11 other locations · NCT07444814

• MEN2501 treatment for platinum-resistant ovarian cancer

  This trial tests a new drug called MEN2501 in adults whose ovarian cancer no longer responds to platinum chemotherapy.

  Recruiting at 15 sites Phase 1 Stemline Therapeutics, Inc. · Springdale, Arkansas and 14 other locations · NCT07226427

• Evaluating SIM0505 for advanced solid tumors

  This study is testing a new treatment called SIM0505 to see if it is safe and effective for adults with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 6 sites Phase 1 NextCure, Inc. · Orlando, Florida and 16 other locations · NCT06792552

• Lorigerlimab for advanced platinum‑resistant and clear‑cell gynecologic cancers

  This trial will test lorigerlimab given by IV every three weeks in people with platinum‑resistant ovarian, fallopian tube, primary peritoneal, or clear‑cell gynecologic cancers.

  Recruiting at 16 sites Phase 2 MacroGenics · Los Angeles, California and 15 other locations · NCT06730347

• Treatment for recurrent platinum-resistant high-grade ovarian cancer using cell therapy and gemcitabine

  This study is testing a new treatment that combines cell therapy and a chemotherapy drug to see if it can help people with recurrent platinum-resistant high-grade ovarian cancer.

  Recruiting at 2 sites Phase 2 ImmunityBio, Inc. · El Segundo, California and 1 other locations · NCT06710288

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• MOv18 IgE treatment for platinum-resistant ovarian cancer

  This study is testing a new treatment called MOv18 IgE for people with platinum-resistant ovarian cancer to see if it can help shrink tumors and improve their health.

  Recruiting at 7 sites Phase 1 Epsilogen Ltd · Bristol and 6 other locations · NCT06547840

• Evaluating CTIM-76 for patients with recurring ovarian and other advanced cancers

  This study is testing a new treatment called CTIM-76 to see if it can help people with hard-to-treat ovarian and other advanced cancers feel better and live longer.

  Recruiting at 11 sites Phase 1 Context Therapeutics Inc. · Little Rock, Arkansas and 15 other locations · NCT06515613

• CIML NK cell therapy for recurrent ovarian cancer

  This study is testing a new treatment using special immune cells to see if it can help people with recurrent high-grade ovarian cancer feel better and improve their health.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06321484

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Combining IN10018 with standard chemotherapy for advanced ovarian cancer

  This study is testing if adding a new drug called IN10018 to standard chemotherapy can help people with advanced ovarian cancer that hasn't responded to other treatments.

  Recruiting at 7 sites Phase 1/2 InxMed (Shanghai) Co., Ltd. · Anyang and 6 other locations · NCT05551507

• Evaluating Olvi-Vec with chemotherapy for advanced ovarian cancer

  This study is testing if a new virus-based treatment called Olvi-Vec, combined with chemotherapy, can help women with tough-to-treat advanced ovarian cancer live longer and feel better.

  Recruiting at 33 sites Phase 3 Genelux Corporation · Mobile, Alabama and 32 other locations · NCT05281471

NIH-funded research (8)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Mitotic MTH1 Inhibitors for Platinum-Resistant Ovarian Cancer

  A treatment approach targeting a specific cancer cell weakness (MTH1) to help women whose ovarian cancer stopped responding to platinum-based therapy.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11421329

• Cirtuvivint plus PARP inhibitor in BRCA/HRD ovarian cancer

  A new treatment approach combines a CLK/DYRK inhibitor with a PARP inhibitor to help women with BRCA mutations or HRD ovarian cancer who have become resistant to platinum therapy.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11398114

• Targeting cancer-specific protein variants to guide T-cell therapy in platinum-resistant ovarian cancer

  Aims to find unique protein variants in platinum-resistant ovarian cancer to guide T-cell receptor therapy for patients.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11332288

• Why some ovarian cancers resist platinum chemotherapy: changes in tumor metabolism

  This project looks at how ovarian tumors change their metabolism when they stop responding to platinum chemotherapy and seeks new targets and markers to help women with recurrent high-grade serous ovarian cancer.

  NIH research Jesse Brown VA Medical Center · Chicago, United States · NIH-11212826

• Cirtuvivint plus olaparib for BRCA/HRD ovarian cancer that stopped responding to platinum

  This work adds cirtuvivint to the PARP drug olaparib to try to help people with BRCA-mutated or homologous recombination–deficient ovarian cancer that no longer responds to platinum chemotherapy.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11179129

• Finding new treatments for platinum-resistant ovarian cancer using T-cell therapy

  This study is looking for new ways to help patients with tough-to-treat ovarian cancer by analyzing their tumor samples to find specific targets that can be attacked by the immune system, which could lead to better treatments for them.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11115806

• Exploring how ovarian cancer cells change metabolism to resist treatment

  This study is looking into why some patients with high-grade serous ovarian cancer stop responding to standard platinum treatments, and it hopes to find new ways to help those patients by understanding how their cancer cells change and adapt.

  NIH research Jesse Brown VA Medical Center · Chicago, United States · NIH-10950330

• Combining new cancer drugs to treat resistant ovarian cancer

  This study is looking at how a new drug called cirtuvivint works with an existing treatment, olaparib, to help patients with platinum-resistant ovarian cancer who have certain genetic mutations, hoping to improve their treatment results and health.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-10852678

Related topics

Quick answers

How many Platinum-resistant Ovarian Cancer clinical trials are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in United States (13 trials), China (4 trials), United Kingdom (3 trials), Australia (2 trials), South Korea (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 11, Phase 3: 3, Phase 2: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →